PuraPharm Sets 26 August Board Meeting to Approve 1H 2026 Results and Mull Interim Dividend
Bulletin Express
Aug 14
PuraPharm Corporation Limited has announced that its board of directors will convene on 26 August 2026. Key agenda items include:
• Review and approval of the Group’s interim results for the six months ended 30 June 2026.
• Authorisation of the related results announcement for public release.
• Deliberation on the declaration of an interim dividend, if deemed appropriate.
The meeting will be chaired by Executive Director and Chairman Chan Yu Ling, Abraham. The board currently comprises three executive directors, two non-executive directors and four independent non-executive directors, ensuring a diversified governance structure ahead of the forthcoming financial disclosures.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.